CB 1 inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.
-THC as well as other cannabinergic ligands including synthetic cannabinoids (e.g., CP 55, 940, WIN 55, 212) and the endogenous ligands anandamide and 2-arachidonoylglycerol (Nakamura- Palacios et al., 1999; Pertwee, 2005) . From a clinical perspective, rimonabant also has been shown to have beneficial effects in the management of obesity and smoking cessation, presumably as a result of its antagonist actions (e.g., Le Foll et al., 2008; Rigotti et al., 2009; Pacher et al., 2006; Padwal and Majumdar, 2007) . Unfortunately, numerous reports describing gastrointestinal side effects such as nausea and emesis as well as mood-depressant actions followed the introduction of rimonabant, hampering its utility and, eventually, resulted in its removal from clinical practice (e.g., Després et al., 2005; Traynor, 2007; Van Gaal et al., 2005) . The adverse effects reported, i.e., nausea and/or emesis and anhedonia or depression-related effects, are opposite to effects in man commonly attributed to CB 1 agonists and, moreover, are not unique to rimonabant. Evidence that other CB1 inverse agonists such as AM251 or taranabant have rimonabant-like profiles of action-including potential adverse effects-have similarly precluded their clinical application (e.g., Addy et al., 2008; Aronne et al., 2010; Pertwee, 2005; Proietto et al., 2010) .
Although the cause of the above-mentioned adverse effects of rimonabant and other CB1 inverse agonists remains unknown, one possibility that has received some attention is that they result from inverse agonist actions at CB 1 receptors (reviewed in This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 3, 2013 as DOI: 10.1124/jpet.112.201962 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET #201962 5 Kirilly et al., 2012; McLaughlin, 2012; Ward and Raffa, 2011) . According to this idea, similar adverse effects might not be observed with CB1 antagonists lacking inverse agonist properties. In this regard, recent data suggest that newly developed CB 1 neutral antagonists, in contrast to CB 1 inverse agonists may not have rimonabant-like effects in laboratory studies. For example, CB1 inverse agonists like rimonabant reduce food intake and body weight but also produce pro-depressant effects in a modified forced swim test (nausea-related effects-gaping in rats or vomiting in ferrets-and prodepressant activity in the peripherally-restricted CB 1 neutral antagonist AM6545 has been shown to reduce food intake and body weight without inducing nausea (or gaping) in rats (Cluny et al., 2010) . Likewise, the centrally-acting CB 1 neutral antagonist AM4113 has been shown to reduce food intake in rats (Cluny et al., 2011) without causing nausea/gaping in rats (Salamone et al., 2007; Sink et al., 2007) , vomiting in ferrets (Chambers et al., 2007; Salamone et al., 2007) , or pro-depressant effects in the rat forced swim test (Jutkiewicz et al., 2010) . Based on such observations, neutral CB 1 antagonists have been forwarded as a promising avenue of drug development that provide clinical benefits like those of rimonabant but, potentially, without its liability for adverse gastrointestinal and/or mood-altering effects (Meye et al., 2012) .
The ability of the inverse agonist rimonabant to dose-dependently antagonize the behavioral effects, including discriminative-stimulus effects, of CB 1 agonists has been well-documented in rodents and nonhuman primates (e.g., Compton et al., 1996; Järbe et al., 2001; McMahon et al., 2005; Wiley et al., 1995) . However, comparable information is not available for CB 1 neutral antagonists, and it is unknown whether the two types of CB 1 ligands are similarly effective as antagonists. Consequently, the This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #201962 6 present studies were conducted to directly compare the antagonist properties of the CB 1 inverse agonist rimonabant and the CB 1 neutral antagonist AM4113 in drug discrimination studies in nonhuman primates. In these studies, subjects were trained to discriminate the novel CB 1 agonist AM4054 (Desai et al., 2012; Thakur et al., submitted) from saline, and several doses of each antagonist were evaluated to permit Schild analysis of their antagonist properties. Schild analysis using data from behavioral studies previously has proven useful for revealing similarities in the receptor-mediated mechanisms of agonist and antagonist action (e.g., Dykstra, Bertalmio, and Woods, 1988; McMahon, 2006a; Paronis and Bergman, 1999; Woods, Winger, and France, 1992) . AM4054, like Δ 9 -THC, is a cannabinoid with <3-fold CB 1 /CB 2 selectivity but with high affinity for the CB1 receptor (K i = 4.9 +/-1.8 nM). Unlike however, AM4054 is a cannabinoid that is characterized as a CB 1 full agonist in functional assays measuring the decrease in forskolin-stimulated cAMP and, as well, the efficacy of translocation following exposure to CB 1 agonists in U2OS cell linesindicated by the ability to form membrane or cytosolic clusters of cannabinoid receptor complexes in CB 1 -E/β-arrestin-GFP (Breivogel and Childers 2000; Sim et al., 1996; Thakur et al., submitted) . Inasmuch as this is the first report of the discriminativestimulus effects of AM4054, pharmacological studies were conducted to examine its potency by i.m. and i.v. routes of administration, its time course of action, and generalization to other CB 1 and non-CB 1 drugs.
METHOD
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Subjects
Nine adult male squirrel monkeys (Saimiri sciureus) were individually housed in a temperature-and humidity-controlled vivarium with a 12-h light/dark cycle (7am-7pm).
Subjects had unlimited access to water in the home cage and were maintained at approximate free-feeding weights by post-session access to a nutritionally balanced diet of high protein banana-flavored biscuits (Purina Monkey Chow, St. Louis, MO) supplemented daily with fresh fruit. Five subjects (31, 101, 103, 115 , and 140) were drug-naïve prior to this study, whereas the remaining subjects (36, 83, 134, and 136) previously had served in studies of behaviorally active drugs (e.g., dopamine agonists and antagonists, opioids) but had not received drug treatments for at least two months prior to the present studies. Experimental sessions were conducted 5 days a week 
Apparatus
During experimental sessions subjects were seated in a Plexiglas chair (Spealman et al., 1977) within a ventilated sound-and light-attenuating enclosure. The front panel of the chair was outfitted with two response levers that were positioned 6 cm left and right of center. Each lever-press with a force of at least 0.25 N closed a microswitch, produced an audible relay click, and was recorded as a response. Red 
Behavioral Procedure
CB 1 discrimination. Subjects initially were trained to terminate visual stimuli associated with the delivery of a brief, low intensity current (200 ms; 3 mA) across the electrodes and, subsequently, to identify injection of the cannabinoid CB 1 agonist AM4054 (0.01 mg/kg, i.m.) in a two-lever drug discrimination procedure. The two levers were designated as the drug (AM4054) and saline levers, with assignment counterbalanced across subjects but remaining the same for a subject throughout the study. AM4054 or saline was administered via intramuscular injection 50 min prior to all training sessions. Each training session began with a 10 min timeout period during which all lights were extinguished and responding had no programmed consequences.
Following the timeout period, two red stimulus lights above each lever were illuminated and completion of ten consecutive responses (FR 10) on the injection-associated 
Drug Testing
After initial training, each of five subjects (31, 101, 103, 115, and 140) was prepared with an intravenous catheter for i.v. drug delivery, using procedures initially described by Herd et al. (1969) . Briefly, under isoflurane anesthesia and in aseptic conditions, one end of a hydrophilically coated polyurethane catheter (inside diameter, 0.635 mm; outside diameter, 1.2 mm) was inserted into a femoral vein and the other end was connected to a subdermal vascular access port (VAP; Access Technologies, Skokie, IL) placed in the subject's mid-lumbar region. In test sessions involving i.v. drug administration in these subjects, the port was accessed by syringe from outside the experimental chamber via a catheter tubing/Huber needle assembly.
Tests for generalization to the training stimulus were conducted when a subject's discrimination performance was at least 90% accurate for 4 of the last 5 sessions and on the immediately preceding session. Procedurally, test sessions differed from training components of 10 trials, each component beginning with a 10-min timeout period. This procedure permitted the determination of the effects of up to 4 incremental i.v. doses of a drug delivered during the sequential timeout periods of a single test session (e.g., Bergman and Spealman, 1988; Lamb et al., 2000; Spealman, 1985) . Third, no current deliveries were scheduled during test sessions so as to preclude possible stimulusinduced enhancement of responding. Other schedule contingencies were unchanged.
In initial experiments, a full range of cumulative doses of the training drug -THC (0.3 mg/kg) were determined i.m. in subjects using single-component sessions that began 5, 15, 60, 120, 240, 480 , and 960 min after injection on separate test days.
Next, to assess the selectivity of discrimination performance, the indirect monoamine agonist cocaine (0.03-1.0 mg/kg), the NMDA non-competitive antagonist ketamine (0.3-3.2 mg/kg), and the opioid agonist morphine (0.32-3.2 mg/kg) also were studied. Doses of each drug ranged from those with no effect on response rate to those that nearly or 
Data Analysis
The two primary dependent measures in the present experiments were response distribution across the two levers and overall response rate. Response distribution (percent AM4054-lever) was calculated by dividing the number of responses on the lever associated with the injection of AM4054 by the total number of responses (excluding any responses during timeout periods). Response rate was calculated by dividing the total number of responses on both levers by the total session time (excluding all timeout periods). Doses of drugs were considered to substitute fully when response distribution was >90% AM4054-lever responding and response rates were >0.2 responses/second.
To quantify alteration in the effects of AM4054 by rimonabant and AM4113, ED 50 values (i.e., the dose resulting in 50% responding on the drug lever) of AM4054 alone and following doses of each pretreatment drug were calculated by interpolation for each subject. Dose ratios were then determined by dividing the ED 50 value when AM4054
This article has not been copyedited and formatted. The final version may differ from this version. was administered with rimonabant or AM4113 by its ED 50 value when administered alone, and Schild plots were constructed by plotting the log (dose ratio -1) as a function of the negative log of molar dose of the pretreatment drug (Arunlakshana and Schild, 1959; Neubig et al., 2003) . If slopes did not differ significantly from unity (i.e., 95% confidence limits included -1 and did not include 0 (e.g., Paronis and Bergman, 1999) , then an apparent pA 2 value (i.e., the dose of pretreatment drug yielding a dose ratio of 2) was determined. All subjects learned to discriminate injections of 0.01 mg/kg AM4054 from saline, with time to criterion performance ranging from approximately 30-60 sessions among subjects. During control sessions following training, injections of the training dose of AM4054 produced on average >99% responding on the AM4054-associated lever, whereas injections of saline produced <1% on the AM4054-associated lever. Response rates following i.m. training doses of AM4054 were somewhat lower than those after saline administration in all subjects, with group averages of 3.1 ±0.6 and 3.6 ±0.7 responses/sec, respectively (mean ±SEM). This small (<20%) difference in response rate was evident at the outset and persisted over the course of the present experiments.
RESULTS

Control performance
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Discriminative-Stimulus Effects of AM4054
The left panels of Figure 1 THC was captured within a 16-hr time frame. All subjects responded exclusively on the saline lever 5 min after injection. Three of four subjects responded on both levers at 15 min, and responding by all subjects occurred exclusively on the AM4054 lever at 1, 2, and 4 hrs. Three of four subjects again responded on both levers after 8 hr, and all subjects responded exclusively on the saline-associated lever 16 hr after injection. As shown in the bottom panel, the averaged effects of ∆ 9 -THC on response rates did not differ substantively from those of AM4054, reflecting similar results for the two drugs among individual subjects (data not shown). Small decreases in response rates were observed 60 min after AM4054 injection, but all effects on response rate throughout the time course determinations for both drugs were slight and within the range of control values for all subjects.
Substitution with CB 1 and non-CB 1 Agonist Ligands
The left panels of Figure 2 show the averaged effects of cumulative i.v. doses of four ) for the regressions was 0.95 and 0.94, respectively, indicating that the quantification of antagonism was orderly across doses. The apparent pA 2 value (95% CL) was 6.9 for both rimonabant (6.8-6.9) and AM4113 (6.5-7.2), with slopes that did not differ significantly from unity (i.e., -1). These analyses are consistent with the view that rimonabant and AM4113 comparably antagonized the CB 1 receptor-mediated discriminative-stimulus effects of AM4054.
DISCUSSION
Results of the present studies indicate that the novel CB 1 agonist AM4054 serves as a highly effective discriminative stimulus in nonhuman primates. Consistent with studies using the related cannabinoid ∆ 9 -THC as a discriminative stimulus (cf., McMahon, 2006a; 2006b; Wiley et al., 1993) , subjects trained to discriminate 0.01 mg/kg AM4054 from saline in the present study reliably generalized drug-lever responding across several common CB 1 ligands (∆ 9 -THC, methanandamide, AM2389). -THC as a CB 1 partial agonist (Burkey et al., 1997; Shen and Thayer, 1999; Petitet et al., 1998; Sim et al., 1996, Thakur et al., submitted) . However, the in vitro distinction in CB 1 efficacy between these drugs was not evident in the present data, showing that -THC also produced full CB 1 -like effects in rats trained with either a low or high training dose of the CB 1 full agonist AM5983-a methodological approach that has been used successfully to distinguish low-and high-efficacy agonists in other pharmacological classes (e.g., Järbe et al., 2012) . Taken together, the present and previous drug discrimination studies of ∆ 9 -THC and other CB 1 agonists are consistent with the idea that, as reported for many behavioral effects of cannabinergic drugs, the receptor occupancy required for CB 1 -mediated discriminative stimulus effects is relatively low (see Gifford et al., 1998) .
The CB 1 inverse agonist rimonabant, in addition to serving as an antagonist in pharmacological studies of cannabinergic drugs, showed initial promise as a novel type of therapeutic for appetitive suppression and smoking cessation (e.g., Le Foll et al., 2008; Rigotti et al., 2009; Pacher et al., 2006; Padwal and Majumdar, 2007) . However, reports of gastrointestinal side effects and mood-depressant actions (e.g., Després et al., 2005; Traynor, 2007; Van Gaal et al., 2005 ) cut short its use in clinical populations, leaving the future development of this class of drugs in doubt. Some investigators have suggested that the therapeutic effects of CB 1 inverse agonists like rimonabant are related solely to their antagonist activity, whereas their undesirable effects stem from the direct consequences of their inverse agonist actions (e.g., Kirilly et al., 2012; Ward and Raffa, 2011) . From this perspective, the development of neutral CB 1 antagonists might yield safer, yet still effective therapeutics for appetite suppression and, possibly, smoking cessation. Indeed, recent laboratory data appear to support this suggestion, indicating that AM4113 and other newly developed CB 1 neutral antagonists may not produce rimonabant-like effects of nausea, emesis, and anhedonia in laboratory animals (e.g., Chambers et al., 2006; Cluny et al., 2010; Cluny et al., 2011; Jutkiewicz et al., 2010; Salamone et al., 2007; Sink et al., 2007) . Importantly, AM4113, like rimonabant, also has been shown to reliably reduce weight gain in laboratory animals, consistent with the idea that its potentially beneficial effects are linked to CB 1 receptor blockade (Chambers et al., 2007; Cluny et al., 2011; Sink et al., 2007) . The present results complement earlier comparisons of CB 1 inverse agonists and neutral antagonists by showing that, notwithstanding differences in efficacy, rimonabant and AM4113 appear to have equally effective antagonist actions, i.e., they surmountably antagonized CB 1 -mediated discriminative-stimulus effects in nonhuman primates with comparable dose-ratio relationships and pA 2 values. In conjunction with available data 
